TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02669069

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS1
Description: Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are synchronous with the tones.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS2
Description: Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS3
Description: Participants in this arm shall be given an audio stimulus which comprises of a sequence of single-frequency tones mixed with a broadband noise with the frequency characteristics of both chosen outside the region of any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
Study: NCT04212728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auotologous AMSCs plus autologous PRP
Description: 150 mL subcutaneous abdominal adipose tissue will be harvested via liposuction . AMSCs will be isolated and cultured from adipose tissue. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.Cultured AMSCs will be collected and suspended by 3ml autologous PRP.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Auotologous PRP
Description: 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
Study: NCT01802645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study: NCT03352050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ground beef
Study: NCT01802645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT04170023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral FD inhibitor
Study: NCT01205282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
Study: NCT01802645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Study: NCT01205282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There will be a 2 week period of placebo run-in.
Study: NCT04440969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Description: Participants will undergo dual-task physical exercises and small group activities comprising of quizzes, puzzles and simulate daily living activities that have been gamified (Mindfun and MindGym, ProAge,Singapore). They will also play games on a touch screen device (computerised cognitive training) that aims to improve cognition in the domains of attention, memory, spatial ability, decision making and cognitive flexibility (Memorie, Neeuro, Singapore) while wearing the Senzeband, which emits low frequency signals on the forehead picked up by four individual sensors, allowing participant to play certain games without touching the device but by attention and focus (https://www.neeuro.com/senzeband).~Dietary guidance will be delivered via a dietary app (Glycoleap). Participants are expected to take photos of their meals daily and upload them onto the app. Certified dieticians will give advice and tips on their choice of food and how to make healthier choices through the app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Description: Participants will undergo dual-task physical exercises and small group activities comprising of quizzes, puzzles and simulate daily living activities that have been gamified (Mindfun and MindGym, ProAge,Singapore). They will also play games on a touch screen device (computerised cognitive training) that aims to improve cognition in the domains of attention, memory, spatial ability, decision making and cognitive flexibility (Memorie, Neeuro, Singapore) while wearing the Senzeband, which emits low frequency signals on the forehead picked up by four individual sensors, allowing participant to play certain games without touching the device but by attention and focus (https://www.neeuro.com/senzeband).~Dietary guidance will be delivered via a dietary app (Glycoleap). Participants are expected to take photos of their meals daily and upload them onto the app. Certified dieticians will give advice and tips on their choice of food and how to make healthier choices through the app.
Study: NCT03574909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
Study: NCT02724761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemic Epinephrine
Description: 1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for racemic epinephrine)
Description: 0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
Study: NCT00972712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib and Tipifarnib
Description: Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)
Study: NCT02721758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Study: NCT03972423

Intervention type: OTHER
Intervention: With or wiyhout a checklist
Description: The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice

Intervention type: OTHER
Intervention: With or wiyhout a checklist
Description: The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
Study: NCT01287338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine
Description: low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine
Description: high dose
Study: NCT03544775

Intervention type: PROCEDURE
Intervention: Isolated General Anesthesia
Description: No nerve block identified through physician billing codes

Intervention type: PROCEDURE
Intervention: Peripheral Nerve Block
Description: Nerve block identified through physician billing codes
Study: NCT04325282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: 1Hz rTMS delivered for 15-20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: sham rTMS delivered for 15-20 minutes
Study: NCT02205970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS (sham)
Description: In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
Study: NCT03818880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Spectacle lens to control progression of myopia
Study: NCT04166149

Intervention type: DIAGNOSTIC_TEST
Intervention: dd-cfDNA Blood Test
Description: The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.

Intervention type: DIAGNOSTIC_TEST
Intervention: dd-cfDNA Blood Test
Description: The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
Study: NCT03017586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beijing Pins Medical Co., Ltd. Deep Brain Stimulator
Description: Deep Brain Stimulation for primary dystonia subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beijing Pins Medical Co., Ltd. Deep Brain Stimulator
Description: Deep Brain Stimulation for primary dystonia subjects
Study: NCT04166149

Intervention type: DIAGNOSTIC_TEST
Intervention: dd-cfDNA Blood Test
Description: The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
Study: NCT02651714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01976078

Intervention type: DRUG
Intervention: Midazolam/Ranitidine/Esomeprazole
Description: Each of the three drugs will be given at 10% of their usual doses for age/weight.
Study: NCT02779465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
Study: NCT01850264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of quadripolar / bipolar LV electrodes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of quadripolar / bipolar LV electrodes
Study: NCT02910583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib administered orally once daily (three 140 mg capsules)
Study: NCT01802645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Study: NCT03242980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured adherence counseling
Description: Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling.
Study: NCT03859050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bronchoscopy with intrabronchial administration of lipopolysaccharide
Description: The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
Study: NCT01902901

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing
Description: Participants will receive Whole Genome Sequencing
Study: NCT01026649

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheterization
Description: Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheterization
Description: Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
Study: NCT00625339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg QD
Study: NCT03493919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ vaccine
Description: Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: One dose of MenACWY vaccine were administered intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: One dose of MenACWY vaccine were administered intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: One dose of MenACWY vaccine were administered intramuscularly at Day 1.
Study: NCT01902901

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Carrier status testing
Description: Carrier status testing

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Carrier status testing
Description: Carrier status testing
Study: NCT02920944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-FNB with 20 gauge ProCore needle
Description: EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with 22 gauge ProCore needle
Description: EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
Study: NCT03485716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: running on a treadmill under normoxia or hypoxia
Description: * 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: running on a treadmill under normoxia or hypoxia
Description: * 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)
Study: NCT02310490

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DA-13-007 right with left side Sculptra left side
Description: The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DA-13-007 left with left side Sculptra right side
Description: The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
Study: NCT01235585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses, once a day for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: Oral dose level 1, once a day for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: Oral dose level 2, once a day for 52 weeks
Study: NCT00660166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK-Cell Infusion
Description: The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
Study: NCT01637558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 hourly LPV/r during TB treatment
Description: 8 hourly LPV/r during TB treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Study: NCT03656900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS BA9/BA46
Description: 10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS BA46/BA9
Description: 10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brain MRI
Description: T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
Study: NCT03099590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: kudzu extract, puerarin
Description: Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Matched sugar beet placebo capsules will serve as placebo.
Study: NCT00493727

Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine(Mucomyst)
Study: NCT05119049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise guideline
Description: The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise guideline
Description: The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
Study: NCT03656900

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brain MRI
Description: T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical evaluation
Description: complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical evaluation
Description: complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
Study: NCT03358147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI 28.8 μg
Description: GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI 14.4 μg
Description: GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID